SOUTH SAN FRANCISCO, Calif.,
Aug. 29, 2016 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced
that the company will announce results of the first of two FIT
Phase 3 studies of fostamatinib for patients with immune
thrombocytopenia (ITP), at 7:00 a.m. Eastern
Time (4:00 a.m. Pacific Time)
on Tuesday, August 30, 2016.
The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3
study results.
Participants can access the live conference call by dialing
855-892-1489 (domestic) or 720-634-2939 (international) and using
the Conference ID number 72149873.
The conference call and accompanying slide presentation will
also be webcast live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and available for
replay after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc. is a clinical-stage biotechnology company
dedicated to the discovery and development of novel, targeted drugs
in the therapeutic areas of immunology, oncology and
immuno-oncology. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
current clinical programs include fostamatinib, an oral spleen
tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical
trials for immune thrombocytopenia (ITP); a Phase 2 clinical trial
for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical
trial for IgA nephropathy (IgAN). In addition, Rigel has two
oncology product candidates in Phase 1 development with partners
BerGenBio AS and Daiichi Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media: Jessica L. Daitch
Chandler Chicco Agency
Phone: 917-816-6712
Email: jessica.daitch@inventivhealth.com
Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-announces-press-release-and-conference-call-schedule-on-tuesday-august-30-2016-300319609.html
SOURCE Rigel Pharmaceuticals, Inc.